Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.005 USD | -3.03% | -2.31% | -46.89% |
Apr. 15 | Earnings Flash (PETS) PETMED EXPRESS Posts Q3 Revenue $65.3M | MT |
Apr. 15 | PetMed Express, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company shows low valuation levels, with an enterprise value at 0.13 times its sales.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-46.89% | 84.23M | C | ||
-15.41% | 8.24B | B | ||
+33.06% | 1.36B | - | ||
+7.36% | 427M | - | ||
+7.36% | 292M | - | ||
+13.33% | 230M | - | - | |
-10.09% | 83.28M | - | - | |
+19.97% | 59.98M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PETS Stock
- Ratings PetMed Express, Inc.